ANI Pharmaceuticals launches generic version of Cymbalta
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- S&P Global explores potential separation of Capital IQ business
- Equities end higher as Anthropic's IPO filing buoys AI stocks
ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules
October 19, 2026 6:55 AM EDTPRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANIs Duloxetine Delayed-Release Capsules are the generic version of the reference listed drug (RLD) Cymbalta®.
By launching Duloxetine Delayed-Release Capsules, ANI is providing another alternative of a widely used therapy in a limited player market to assure stable supply. Through close customer and manufacturer partnerships and a focused regulatory effort, we are proud to make this important and widely used therapy... More



